Trials / Completed
CompletedNCT02173457
Study of Chiglitazar Compare With Sitagliptin in Type 2 Diabetes Patients
Phase III Study of Chiglitazar in Patients With Type 2 Diabetes Mellitus and Insufficient Glycemic Control Despite Diet and Exercise -- A Multicenter, Randomized, Double-Blind, and Sitagliptin-Controlled Trial
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 740 (actual)
- Sponsor
- Chipscreen Biosciences, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with Sitagliptin.
Detailed description
The efficacy and safety will be compared between Chiglitazar and Sitagliptin after treatment of 24 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Chiglitazar | Take orally |
| DRUG | Sitagliptin | Take orally |
Timeline
- Start date
- 2014-09-01
- Primary completion
- 2017-01-01
- Completion
- 2017-01-01
- First posted
- 2014-06-25
- Last updated
- 2019-10-25
Locations
37 sites across 1 country: China
Source: ClinicalTrials.gov record NCT02173457. Inclusion in this directory is not an endorsement.